Paid Clinical Trials for Solid Tumors

Showing 21 – 34 of 34 results

QTX3034 in Patients With KRAS G12D Mutation

by CTG

in Solid Tumors

Other

California

Deadline:

04/01/2027

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

by CTG

in Solid Tumors

Other

New York

Deadline:

08/01/2026

A Study of DF6002 Alone and in Combination With Nivolumab

by CTG

in Solid Tumors

Other

California

Deadline:

11/30/2027

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

by CTG

in Solid Tumors

Other

California

Deadline:

06/30/2030

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

by CTG

in Liver Cancer, Gastrointestinal Cancer, Solid Tumors, Hematologic Malignancy, Pancreatic Cancer

Other

Maryland

Deadline:

06/15/2033

A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

by CTG

in Solid Tumors

Other

California

Deadline:

03/27/2027

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

by CTG

in Pancreatic Ductal Adenocarcinoma (PDAC), Solid Tumors, Gastric Cancer, Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer

Other

California

Deadline:

01/26/2028

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

by CTG

in Hematologic Malignancies, Solid Tumors

Other

Arizona

Deadline:

08/04/2043

A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

by CTG

in Solid Tumors

Other

California

Deadline:

12/01/2026

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

by CTG

in Solid Tumors

Other

Arizona

Deadline:

12/31/2026

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

by CTG

in Solid Tumors

Other

Florida

Deadline:

07/01/2027

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

by CTG

in Solid Tumors, Sarcoma

Other

Tennessee

Deadline:

11/30/2028

A Study of ADRX-0706 in Select Advanced Solid Tumors

by CTG

in Solid Tumors

Other

California

Deadline:

12/01/2026

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

by CTG

in Solid Tumors, Lymphoma

Other

New York

Deadline:

10/01/2027

QTX3034 in Patients With KRAS G12D Mutation

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

A Study of DF6002 Alone and in Combination With Nivolumab

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

A Study of ADRX-0706 in Select Advanced Solid Tumors

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps

Get new clinical trials sent to you?

Paid Clinical Trials for Solid Tumors

Filter Results:

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps